Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.73 – $17.18
82% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.0M | $14.0M | $0 | $3.8K | $57.3K | $813.5M |
| Cost of revenue | $19.1K | $15.3K | $800.0K | $1.6M | $307.4K | $16.0K | $3.9M | $303.3M |
| Gross profit | −$19.1K | −$15.3K | $1.2M | $12.4M | −$307.4K | −$12.2K | −$3.9M | $510.2M |
| Gross margin | — | — | 60.0% | 88.6% | — | -322.6% | -6749.5% | 62.7% |
| R&D | $11.1M | $14.1M | $13.3M | $14.9M | $13.1M | $13.0M | $14.5M | $1.91B |
| Operating income | −$17.3M | −$21.3M | −$19.8M | −$12.9M | −$26.9M | −$25.4M | −$48.7M | −$46.7M |
| EBITDA | −$17.2M | −$21.3M | −$19.7M | −$12.2M | −$26.3M | −$24.1M | −$46.2M | $656.0M |
| Net income | −$17.3M | −$21.0M | −$19.7M | −$12.8M | −$27.7M | −$27.3M | −$49.8M | −$47.00B |
| Net margin | — | — | -984.6% | -91.3% | — | -719859.9% | -86888.6% | -5777.7% |
| EPS (diluted) | -1.82 | -1.46 | -0.94 | -39.20 | -66.59 | -53.15 | -59.81 | 0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-14.40 | $-14.40–$-14.40 | 1 |
| 2027 | $24M | $-10.85 | $-10.85–$-10.85 | 1 |
| 2028 | $42M | $-4.21 | $-4.21–$-4.21 | 1 |
| 2029 | $64M | $1.40 | $1.40–$1.40 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds EYEN.
No tracked institution reports a position in EYEN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-02-03 | 1-for-80reverse |
No one on the platform has traded EYEN yet.
| $38M |
| — |
| MGTAMagenta Therapeutics, Inc. | $0.70 | -7.74% | $42M | — |
| MRNSMarinus Pharmaceuticals, Inc. | $0.55 | +0.00% | $30M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 188.0× sales vs its 1015.2× historical median P/S.
Fair value ≈ $85.44 · price $15.82 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.